In a chilled low-pressure room that contrasts sharply with the humid Maltese weather outside, a poster reminds the white-coated staff of Actavis that they have just six weeks to finish work on a new drug.

Every day counts as the 320 employees of the generic-drugs manufacturer finalise their latest launch, exploiting an anomaly with patents that is turning the tiny Mediterranean island into an unexpected investment location for the pharmaceutical industry.